Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Göhler

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
BMC Cancer|February 12, 2016
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation studyAlexander Stein, Julia Quidde, Jan Klaus Schröder, et al.
The Oncologist|February 9, 2017
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in GermanyPeter Dall, Thorsten Koch, Thomas Göhler, et al.
BMC Cancer|January 10, 2018
Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational studyPeter Dall, Thorsten Koch, Thomas Göhler, et al.
Journal of Geriatric Oncology|September 6, 2015
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in GermanyPeter Dall, Gertrud Lenzen, Thomas Göhler, et al.
Anticancer Research|December 6, 2015
Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional StudyRadoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
International Journal of Cancer|September 9, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATEKarin Potthoff, Jens Uhlig, Lutz Jacobasch, et al.
BMC Cancer|September 30, 2020
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
Cancers|July 24, 2021
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck CancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
International Journal of Cancer|March 6, 2026
Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA studyPeter A Fasching, Cosima Brucker, Thomas Decker, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
BMC Cancer|February 12, 2016
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation studyAlexander Stein, Julia Quidde, Jan Klaus Schröder, et al.
The Oncologist|February 9, 2017
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in GermanyPeter Dall, Thorsten Koch, Thomas Göhler, et al.
BMC Cancer|January 10, 2018
Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational studyPeter Dall, Thorsten Koch, Thomas Göhler, et al.
Journal of Geriatric Oncology|September 6, 2015
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in GermanyPeter Dall, Gertrud Lenzen, Thomas Göhler, et al.
Anticancer Research|December 6, 2015
Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional StudyRadoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
International Journal of Cancer|September 9, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATEKarin Potthoff, Jens Uhlig, Lutz Jacobasch, et al.
BMC Cancer|September 30, 2020
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
Cancers|July 24, 2021
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck CancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
International Journal of Cancer|March 6, 2026
Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA studyPeter A Fasching, Cosima Brucker, Thomas Decker, et al.
Pageof 3